Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Neuroblastoma 4Ganglioneuroblastoma 2Sarcoma 1Osteosarcoma 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Melanoma 1Medulloblastoma 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia 1Congenital Abnormalities 1Central Nervous System Neoplasms 1Brain Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cytarabine 15Daunorubicin 9Gemtuzumab 7Filgrastim 6sargramostim 5Gene Expression Profiling 5Flow Cytometry 5Mitoxantrone 4Idarubicin 4Etoposide 4Peripheral Blood Stem Cell Transplantation 3Clofarabine 3Polymerase Chain Reaction 2Observation 2Immunologic Techniques 2Granulocyte Colony-Stimulating Factor 2DNA Methylation 2Asparaginase 2zosuquidar trihydrochloride 1valspodar 1fludarabine phosphate 1etoposide phosphate 1Topotecan 1Thiotepa 1Thioguanine 1Reverse Transcriptase Polymerase Chain Reaction 1Radiotherapy 1Pharmacogenomic Testing 1Microarray Analysis 1Methotrexate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Leukemia, Monocytic, Acute × Colony-Stimulating Factors × Clear all
NCT00046930 2023-07-05

Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia

Eastern Cooperative Oncology Group

Phase 3 Completed
449 enrolled 9 charts
Classical hematologyMyeloidOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, with Excess of Blasts, Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡